Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
Tilray Brands, Inc. operates as a global lifestyle and consumer packaged goods company spanning cannabis, craft beverages, hemp-based foods and wellness products. News about TLRY commonly covers product launches, brand refreshes and retail distribution across beverage and food subsidiaries such as BrewDog, 10 Barrel Brewing, SweetWater Brewing Company, Widmer Brothers Brewing and Manitoba Harvest.
Company updates also address Tilray Medical, international medical cannabis markets, Canadian adult-use and medical cannabis activity, quarterly operating results, acquisitions and capital actions. Recurring coverage links Tilray’s cannabis platform with its beverage and wellness portfolio across North America, Europe and other international markets.
Tilray (NASDAQ: TLRY) announced encouraging results from a clinical trial led by Australian researchers, demonstrating its GMP-produced cannabis product's potential to reduce chemotherapy-induced nausea and vomiting. The study, published in the Annals of Oncology, noted that 25% of patients using medicinal cannabis experienced no vomiting or nausea, compared to 14% of those on a placebo. Following this pilot phase with 81 participants, a larger trial will begin, recruiting an additional 170 participants to assess effectiveness further.